Clinical Trial Update: Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey

View source ↗

Summary

Pfizer-sponsored analysis comparing patient-reported outcomes for rimegepant versus triptans in migraine using data from the 2023 National Health and Wellness S…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• Rimegepant (rimegepant)
• Triptans (class)

Snippet

Sponsor: Pfizer | Conditions: Migraine | Status: COMPLETED | Results posted: 2026-01-22